Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430040 · ClinicalTrials.gov registry record · Phase 4
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
A Phase 4 study, sponsored by University at Buffalo.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00430040 is a Phase 4 study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 14 participants.
The verdict
NCT00430040, a Phase 4 study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is believed that carvedilol provides added benefits by suppressing free radicals(charged substances that cause damage to the body ) and inflammation.
Interventions
- DRUG lisinopril
- DRUG Carvedilol Controlled Release (CR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430040
The ClinicalTrials.gov registry entry for NCT00430040 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lisinopril is the first listed.
NCT00430040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430040 about?
NCT00430040 is a clinical study titled "Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.". To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is believed that carvedilol provides added benefits by suppressing free radical...
What is the current status of trial NCT00430040?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2007-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00430040?
The interventions under investigation include: lisinopril (DRUG), Carvedilol Controlled Release (CR) (DRUG).
Who is sponsoring clinical trial NCT00430040?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.